SK287523B6 - Použitie CC chemokínového mutanta, farmaceutický prostriedok s obsahom chemokínového mutanta, skrátený a mutovaný humánny RANTES a spôsob jeho výroby - Google Patents
Použitie CC chemokínového mutanta, farmaceutický prostriedok s obsahom chemokínového mutanta, skrátený a mutovaný humánny RANTES a spôsob jeho výroby Download PDFInfo
- Publication number
- SK287523B6 SK287523B6 SK406-2003A SK4062003A SK287523B6 SK 287523 B6 SK287523 B6 SK 287523B6 SK 4062003 A SK4062003 A SK 4062003A SK 287523 B6 SK287523 B6 SK 287523B6
- Authority
- SK
- Slovakia
- Prior art keywords
- ala
- mutant
- rantes
- ser
- lys
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00121665 | 2000-10-04 | ||
PCT/EP2001/011428 WO2002028419A2 (en) | 2000-10-04 | 2001-10-03 | Chemokine mutants in the treatment of multiple sclerosis |
Publications (2)
Publication Number | Publication Date |
---|---|
SK4062003A3 SK4062003A3 (en) | 2003-08-05 |
SK287523B6 true SK287523B6 (sk) | 2011-01-04 |
Family
ID=8170011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK406-2003A SK287523B6 (sk) | 2000-10-04 | 2001-10-03 | Použitie CC chemokínového mutanta, farmaceutický prostriedok s obsahom chemokínového mutanta, skrátený a mutovaný humánny RANTES a spôsob jeho výroby |
Country Status (31)
Country | Link |
---|---|
US (1) | US7402303B2 (zh) |
EP (1) | EP1326628B1 (zh) |
JP (1) | JP3908165B2 (zh) |
KR (1) | KR100837898B1 (zh) |
CN (1) | CN1285381C (zh) |
AR (1) | AR030854A1 (zh) |
AT (1) | ATE265222T1 (zh) |
AU (2) | AU2002215919B2 (zh) |
BG (1) | BG66137B1 (zh) |
BR (1) | BR0114407A (zh) |
CA (1) | CA2423616C (zh) |
CZ (1) | CZ303409B6 (zh) |
DE (1) | DE60103078T2 (zh) |
DK (1) | DK1326628T3 (zh) |
EA (1) | EA006137B1 (zh) |
EE (1) | EE05174B1 (zh) |
ES (1) | ES2217199T3 (zh) |
HK (1) | HK1062811A1 (zh) |
HR (1) | HRP20030215B1 (zh) |
HU (1) | HUP0302194A3 (zh) |
IL (2) | IL155178A0 (zh) |
MX (1) | MXPA03003008A (zh) |
NO (1) | NO330278B1 (zh) |
PL (1) | PL204231B1 (zh) |
PT (1) | PT1326628E (zh) |
RS (1) | RS50738B (zh) |
SI (1) | SI1326628T1 (zh) |
SK (1) | SK287523B6 (zh) |
UA (1) | UA77950C2 (zh) |
WO (1) | WO2002028419A2 (zh) |
ZA (1) | ZA200302315B (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005525089A (ja) | 2001-12-17 | 2005-08-25 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | ケモカイン・アンタゴニストとして作用するケモカイン突然変異体 |
DE60303929T2 (de) * | 2002-04-04 | 2006-08-10 | Applied Research Systems Ars Holding N.V. | Chemokin-muntanten mit verbesserter oraler bioverfügbarkeit |
WO2004062688A2 (en) * | 2002-12-23 | 2004-07-29 | Applied Research Systems Ars Holding N.V. | Use of cc-chemokine mutants against liver diseases |
DE602004018014D1 (de) * | 2003-10-22 | 2009-01-08 | Serono Lab | Cxcl8-antagonisten |
AT412785B (de) * | 2003-12-04 | 2005-07-25 | Kungl Andreas J Dr | Gag-bindungsproteine |
DE60304435T2 (de) * | 2004-01-19 | 2006-08-24 | Ares Trading S.A. | Verfahren zur Reinigung von in Bakterien exprimierten Proteinen |
GB0412400D0 (en) * | 2004-06-03 | 2004-07-07 | Univ Newcastle | Treatment of inflammatory conditions |
EP1760110B1 (en) * | 2005-09-03 | 2011-11-02 | Samsung SDI Co., Ltd. | Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane |
GB0614755D0 (en) | 2006-07-25 | 2006-09-06 | Univ Geneve | Cytokine derivatives |
MX2010001307A (es) | 2007-08-02 | 2010-07-30 | Novimmune Sa | Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos. |
AU2011213559B2 (en) * | 2010-02-08 | 2015-05-07 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same |
CA3101052A1 (en) | 2018-05-28 | 2019-12-05 | ORION Biotechnology Switzerland Sarl | Methods of inhibiting cerebral inflammation |
WO2022093857A1 (en) * | 2020-10-26 | 2022-05-05 | City Of Hope | Oncolytic virus compositions and methods for the treatment of cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5739103A (en) * | 1993-11-12 | 1998-04-14 | Dana-Farber Cancer Institute | Chemokine N-terminal deletion mutations |
WO1998006751A1 (en) * | 1996-08-16 | 1998-02-19 | Research Corporation Technologies, Inc. | Mcp-3, rantes and mip-1alpha receptor antagonists |
EP0906954A1 (en) * | 1997-09-29 | 1999-04-07 | Applied Research Systems ARS Holding N.V. | Amino-terminal truncated c-c chemokines as chemokine antagonist |
DE69832216T2 (de) * | 1997-12-23 | 2006-05-24 | Fondazione Centro San Raffaele Del Monte Tabor | RANTES-Mutanten und therapeutische Anwendungen davon |
AU2740900A (en) * | 1999-01-29 | 2000-08-18 | Millennium Pharmaceuticals, Inc. | Method of treating demyelinating inflammatory disease using ccr1 antagonists |
-
2001
- 2001-03-10 UA UA2003044038A patent/UA77950C2/uk unknown
- 2001-10-03 AT AT01986265T patent/ATE265222T1/de active
- 2001-10-03 PT PT01986265T patent/PT1326628E/pt unknown
- 2001-10-03 PL PL362350A patent/PL204231B1/pl not_active IP Right Cessation
- 2001-10-03 AU AU2002215919A patent/AU2002215919B2/en not_active Ceased
- 2001-10-03 KR KR1020037004599A patent/KR100837898B1/ko not_active IP Right Cessation
- 2001-10-03 EP EP01986265A patent/EP1326628B1/en not_active Expired - Lifetime
- 2001-10-03 WO PCT/EP2001/011428 patent/WO2002028419A2/en active IP Right Grant
- 2001-10-03 EA EA200300439A patent/EA006137B1/ru not_active IP Right Cessation
- 2001-10-03 HU HU0302194A patent/HUP0302194A3/hu unknown
- 2001-10-03 CA CA2423616A patent/CA2423616C/en not_active Expired - Fee Related
- 2001-10-03 DK DK01986265T patent/DK1326628T3/da active
- 2001-10-03 MX MXPA03003008A patent/MXPA03003008A/es active IP Right Grant
- 2001-10-03 EE EEP200300139A patent/EE05174B1/xx not_active IP Right Cessation
- 2001-10-03 ES ES01986265T patent/ES2217199T3/es not_active Expired - Lifetime
- 2001-10-03 ZA ZA200302315A patent/ZA200302315B/en unknown
- 2001-10-03 DE DE60103078T patent/DE60103078T2/de not_active Expired - Lifetime
- 2001-10-03 JP JP2002532243A patent/JP3908165B2/ja not_active Expired - Fee Related
- 2001-10-03 BR BR0114407-3A patent/BR0114407A/pt not_active IP Right Cessation
- 2001-10-03 AU AU1591902A patent/AU1591902A/xx active Pending
- 2001-10-03 CN CNB018199178A patent/CN1285381C/zh not_active Expired - Fee Related
- 2001-10-03 CZ CZ20030947A patent/CZ303409B6/cs not_active IP Right Cessation
- 2001-10-03 US US10/398,457 patent/US7402303B2/en not_active Expired - Fee Related
- 2001-10-03 SK SK406-2003A patent/SK287523B6/sk not_active IP Right Cessation
- 2001-10-03 RS YUP-257/03A patent/RS50738B/sr unknown
- 2001-10-03 SI SI200130130T patent/SI1326628T1/xx unknown
- 2001-10-03 IL IL15517801A patent/IL155178A0/xx unknown
- 2001-10-04 AR ARP010104684A patent/AR030854A1/es unknown
-
2003
- 2003-03-20 HR HR20030215A patent/HRP20030215B1/xx not_active IP Right Cessation
- 2003-03-28 BG BG107685A patent/BG66137B1/bg unknown
- 2003-04-01 IL IL155178A patent/IL155178A/en not_active IP Right Cessation
- 2003-04-03 NO NO20031525A patent/NO330278B1/no not_active IP Right Cessation
-
2004
- 2004-08-02 HK HK04105657A patent/HK1062811A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018372167B2 (en) | Partial agonists of interleukin-2 | |
US7425324B2 (en) | Antagonists of MCP proteins | |
SK287523B6 (sk) | Použitie CC chemokínového mutanta, farmaceutický prostriedok s obsahom chemokínového mutanta, skrátený a mutovaný humánny RANTES a spôsob jeho výroby | |
Huang et al. | The bifunctional SDF‐1‐AnxA5 fusion protein protects cardiac function after myocardial infarction | |
MXPA06003695A (es) | Usos terapeuticos de variantes de quimiocinas. | |
AU2002215919A1 (en) | Chemokine mutants in the treatment of multiple sclerosis | |
AU2003288434A1 (en) | Peptides, antibodies thereto, and their use in the treatment of central nervous system damage | |
JP2023526218A (ja) | 生体高分子標的特異的補体阻害剤及びその製造方法と応用 | |
US7932227B1 (en) | Lacritin-syndecan fusion proteins | |
US6329500B1 (en) | Transforming growth factor-β binding site | |
WO2005056581A2 (en) | Peptide able to specifically bind a chemokine receptor and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TC4A | Change of owner's name |
Owner name: MERCK SERONO SA, COINSINS, VAUD, CH Effective date: 20120709 |
|
MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20131003 |